Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 30, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 2,750,000 Ordinary shares.
- Purchase Price: 1,112.67 pence per share.
- Purchase Date: June 30, 2008.
- Treasury Shares Held: 474,194,158 shares (representing 8.97% of total voting rights).
- Shares in Issue: 5,287,539,849 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,750,000 shares purchased on June 30, 2008. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback.
Investor Verification Checklist
- Verify the total cost of the repurchase (2,750,000 shares x 1,112.67 pence).
- Confirm the updated total voting rights denominator (5,287,539,849 shares) for disclosure threshold calculations.
- Review the impact of the 8.97% Treasury holding on earnings per share (EPS) metrics in subsequent financial reports.
- Check the remaining authorization limit for share buybacks following this transaction.